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OBJECTIVES: In Brazil, imatinib mesylate is supplied as the first-line therapy for chronic myeloid leukemia in
the chronic phase through the public universal healthcare program, Sistema U´nico de Sau´de (SUS). We
studied the socio-demographic factors that influenced therapy success in a population in the northeast region
of Brazil.
METHODS: Patients with chronic myeloid leukemia from the state of Piauı´ were treated in only one reference
center. Diagnosis was based on WHO 2008 criteria. Risk was assessed by Sokal, Hasford and EUTOS scores.
Patients received 400 mg imatinib daily. We studied the influence of the following factors on the achievement
of complete cytogenetic response within one year of treatment: age, clinical risk category, time interval
between diagnosis and the start of imatinib treatment, geographic distance from the patient’s home to the
hospital, years of formal education and monthly income.
RESULTS: Among 103 patients studied, the median age was 42 years; 65% of the patients had 2–9 years of
formal education, and the median monthly income was approximately 100 US$. Imatinib was started in the first
year after diagnosis (early chronic phase) in 69 patients. After 12 months of treatment, 68 patients had a
complete cytogenetic response. The Hasford score, delay to start imatinib and years of formal education
influenced the attainment of a complete cytogenetic response, whereas income and the distance from the
home to the healthcare facility did not.
CONCLUSION: Patients require additional healthcare information to better understand the importance of
long-term oral anticancer treatment and to improve their compliance with the treatment.
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’ INTRODUCTION
The approval of imatinib (IM) as a targeted therapy for
chronic myeloid leukemia (CML) by the Federal Drug
Agency (FDA) in 2001 has opened a new era in the treatment
of this disease and has considerably improved patients’
survival (1–5). In Brazil, the Ministry of Health initially
approved IM for CML in the chronic phase as a second-line
treatment and in 2008 as front-line therapy (6,7). The drug is
provided for free to all Brazilian residents through the public
health program, Sistema Único de Saúde (SUS). Additionally,
recently published national guidelines regulate the cytoge-
netic and molecular monitoring of patients (7).
In the first Brazilian publication on the results of using IM,
presented by a center from São Paulo participating in
international cooperative studies (8), 68.8% of the patients
starting treatment in the early chronic phase achieved a
complete cytogenetic response (CCyR) within 12 months.
However, it might be expected that the large social and
educational inequalities of the Brazilian population could
influence the treatment outcome. Thus, we evaluated socio-
economic factors influencing the treatment success of
patients with CML treated in the state of Piauí, located in
the northeast region of Brazil.DOI: 10.6061/clinics/2015(05)03
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’ PATIENTS AND METHODS
All consecutive patients diagnosed with CML in the chronic
phase treated at the São Marcos Hospital in Teresina, Piauí,
between February 2004 and February 2013 were included in
the study. This hospital is the only reference center for CML
treatment in the state of Piauí and also treats some patients
from the neighboring state of Maranhão. Diagnosis was based
on clinical data, peripheral blood counts and cytogenetics or
on the detection of the BCR-ABL1 rearrangement by multiplex
PCR. Cytogenetics and molecular tests were performed at the
central laboratory of the National Institute of Cancer (INCA)
in Rio de Janeiro. Patients’ risk categories were assessed by the
Sokal, Hasford and EUTOS scores (9–11).
Patients diagnosed before 2008 and who were treated first
with hydroxyurea or interferon but were intolerant to these
medications and were thus switched to imatinib were also
included in the study. The diagnosis of chronic or accelerated
phase disease and blast crisis was performed according to
the WHO 2008 criteria (12). Patients were considered to be in
the early chronic phase when imatinib therapy was started
before 12 months following diagnosis.
For each patient, we collected the geographic distance
from the patient’s home to the hospital (in kilometers), the
years spent in school, the average monthly income of each
family member and the time interval between diagnosis and
the start of imatinib treatment. The per capita income was
also grouped into the income classes established by the
Brazilian government (Secretariat of Strategic Affairs).
All patients received 400 mg imatinib daily. Previous
treatments included hydroxyurea or interferon. All patents
provided informed consent for their participation in the
study, which was approved by the local Ethics Committee
(proc. no. 045 - 2010 – Federal University of Piauí).
Laboratory monitoring comprised monthly peripheral
blood counts performed by local laboratories. Karyotyping
was scheduled to be performed at 3, 6 and 12 months; however,
in some cases, karyotyping was only possible with some delay.
After achieving a complete cytogenetic response, molecular
monitoring (quantitative PCR) was performed every 3 months.
The response criteria were evaluated according to the 2009
European LeukemiaNet (ELN) guidelines (13).
All time-to-event analyses were made with the log-rank
test or Cox regressions. All time-to-event calculations were
based on the interval between the beginning of imatinib
treatment and the complete cytogenetic response. Cases were
censored when there was no response after the third
karyotyping (approximately 12 months) or when the patients
changed therapy or dropped out of the study before the
end of the study. Non-normally distributed variables were
normalized by logarithmic transformation. All variables
presenting po0.15 were included in the multivariate analysis.
A bootstrap resampling procedure was performed to test the
stability of the model, as previously described (14–17). Winstat
3.1 and SPSS 15.0 software were used.
’ RESULTS
A total of 103 patients with CML in the chronic phase
entered this study. Their descriptive data are summarized
in Table 1. Among the patients, 101 were Ph+ (had a
Philadelphia chromosome) in the cytogenetic examination;
the remaining two had normal karyotypes and were BCR-
ABL1 positive.
All patients had received hydroxyurea for cytoreduction
until the result of karyotyping was received, and 35 had also
received interferon. Regarding the delay before imatinib
treatment, 69 patients were in the early chronic phase, and
the remaining 34 started imatinib more than one year
following diagnosis. The median time of imatinib treatment
in the patients was 45 months (range 7–141). At the end of
the observation period, 70 patients (68%) remained on this
tyrosine kinase inhibitor (TKI). Imatinib was discontinued
due to a loss of response in 28 cases and disease progression
in 5 cases. One patient received an allogeneic bone marrow
transplantation, and two were lost to follow-up. Among the
68 patients who had achieved a CCR within approximately
one year, only 8 later became resistant or progressed.
According to the income classes, 12 patients earned
between 0 and 81 reais, 17 between 82-162 reais, 38 between
163-441 reais, 18 between 292-441 reais, 9 between 442-641
and 9 had an income 4642 reais.
The median time of formal education of the patients was 4
years (Table 1). Eleven patients had never gone to school or
had attended school for only one year, 67 patients had spent
2–9 years in school, 17 had spent between 10–12 years in
school, and only 8 had some university education (413 years
of education). There was a positive correlation (r=0.20;
p=0.012) between the patients’ income and the years they
had spent in school (Figure 1). However, the distribution of
the patients according to the risk groups of any of the scores
assessed was not affected by their income classes or years of
formal education. Most patients lived far from the healthcare
facilities (Table 1).
In the Kaplan-Meier plot, the median time to remission for
patients with 1 year or less spent in school was 404 days. The
median time to remission was 369 days for both the groups
with 2 to 9 years of education (basic level) and with 10 to
12 years of education (secondary level) and was 252 days for
Table 1 - Features of the patients at diagnosis.
Variable Value
Gender (for all 103 cases)
Male 56
Female 47
Age in years (median, range) 42 (8–81)
Sokal score (100 cases)
Low risk 30
Intermediate risk 42
High risk 28
Hasford score (100 cases)
Low risk 67
Intermediate risk 27
High risk 6
EUTOS score (99 cases)
Low risk 92
Intermediate risk 7
Treatment before imatinib (no. Patients)
Hydroxyurea 103
Interferon-a 34
Median interval diagnosis - start imatinib (days) 99 (27–1780)
For patients in early chronic phase (days) 60
For patients in late chronic phase (days) 963
Years in school 4 (0–17)
Median income per family member and month
(in R$)*
226.00 (9.00–3,000.00)
Distance from the home to the hospital (in km) 150 (1–794)
* These values correspond to a mean of 1 Real=0.5 US$ during the study
period
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patients with 13 or more years of education (university level)
(log-rank test p=0.006) (Figure 2).
In the Cox regression analysis, the Sokal score was of no
prognostic relevance, in contrast with the Hasford (p=0.03)
and EUTOS (p=0.08) scores. The delay between diagnosis
and start of the imatinib therapy was an unfavorable
predictive factor for complete cytogenetic remission
(B=-0.001; p=0.02), and age was a weak risk factor
(B=-0.013; p=0.117). Concerning the demographic and socio-
economic variables, only the educational level had a
significant influence on the time to acquire a complete
cytogenetic response (B=0.065; p=0.008). Gender, income and
the distance from the home to the health facility did not
affect the cytogenetic response.
In the multivariate Cox regression analysis, considering
age, Hasford and EUTOS scores, years spent in school and
the delay to begin IM treatment, only the Hasford score
(B=-0.531; p=0.038) and years spent in school remained as
independent predictive factors (B=0.374; p=0.019). In the
bootstrap stability test, ‘‘Hasford score’’ was present in 71%
of the new sets, ‘‘years in school’’ was present in 62%, ‘‘delay
to begin imatinib’’ appeared in 32%, and ‘‘EUTOS score’’
appeared in 18%.
’ DISCUSSION
The introduction of targeted therapy with TKIs has
substantially improved the life expectancy and quality of
life of patients with CML. However, it has repeatedly been
observed that treatment results in daily praxis do not
reproduce those of clinical trials (2,3). The reasons for this
observation have been a matter of debate, but more recent
data have shown that the results in population-based patient
cohorts may be equally good, provided that drug access is
unrestricted (3). Since 2008, the Brazilian public healthcare
system has provided IM as the first-line treatment for CML
for every resident in the country. The main question of our
study was to investigate whether the significant social
inequalities in the population could be of major clinical
importance for the success of long-term TKI treatment for
CML. Notably, in our study, the socioeconomic or educa-
tional level was not related to the stage of disease at
diagnosis.
Among our patients, the only demographic factor influen-
cing the optimal cytogenetic response according to the ELN
criteria was the education level, whereas personal income
and the distance between home and the health care facility
did not. In a population with unrestricted access to
medication, patients with a better education level may better
understand the disease mechanism and the importance of
long-term treatment, as has been previously noted (4,5,19).
Social and educational inequalities have also been shown to
influence breast cancer mortality (20) as well as the normal
development of low birth weight children (21).
The fact that a family’s earnings do not affect therapy is
surprising at first glance. The literature is contradictory in
this regard (3,5,22–24). On the one hand, familial resources
have been reported to have a significant influence on the
outcome of acute lymphoid leukemia (ALL) in both
developing and wealthier countries (22,24). Patient malnour-
ishment and lack of family support have also been implicated in
a patient’s incapacity to maintain long-term treatment. On
the other hand, family earnings did not affect the outcomes
of children with ALL in Norway (23) and the United
Kingdom (24), where the public health system provides
state of the art treatment for all patients. Nevertheless,
several publications have called attention to the fact that
better educated patients and those with good family support
have much better outcomes after cancer treatment, especially
with oral anti-cancer agents, in European countries (5,23).
Highly educated patients read more, better understand the
nature of their disease, and are more perseverant and more
motivated to adhere to long-lasting treatments, regularly
using the prescribed drugs and even arriving at the hospital
on the appropriate day (4,5,19,23). This was fully confirmed
in the present study, in which the years spent in school was a
strong predictive factor for an optimal cytogenetic response.
According to the Kaplan-Meier curve, it was evident that
many patients with only one year of formal education
delayed the third cytogenetic control. However, even
after eliminating these patients from the survival curve, the
log rank test still indicated significant differences. As the
Figure 2 - Kaplan-Meier plot analyzing the median time to
complete cytogenetic remission according to the patients’
educational levels: 0–1 year spent in school (median 404 days),
2–9 years (basic level), 10–12 years (secondary level) (median 369
days) and X13 years (university level) (median 252 days). Log-
rank test p = 0.006.
Figure 1 - Patient distribution according to their income and
years of formal education. Spearman’s rank order correlation
was significant between the two variables: r = 0.20; p = 0.012.
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Kaplan-Meier curve suggests, patients with at least some
university education show the best therapy success. A
similar finding was reported from Norway, where the
outcomes in children with cancer were better when the
mothers were highly educated (23). Additionally, in a former
work, performed in a more affluent region of our country
(19), the time of TKI treatment, participation in clinical trial,
higher quality of life scores and socioeconomic statuses,
measured by the patients’ income and education levels,
respectively, influenced IM treatment compliance.
Although we have found a significant correlation between
income and education level, only the years of formal
education influenced achievement of CCyR within one year
of IM treatment. This finding is in agreement with the
hypothesis that in a setting where all patients have equal
access to oral anticancer therapy, the patients’ capacity to
understand the importance of their treatment is essential for
good compliance. It is even more important for the long-term
maintenance of therapy. Thus, to optimize the invested
public resources in drugs and laboratory support, broad
additional healthcare information for patients is necessary.
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